GENinCode (LON:GENI) Stock Price Down 9.6% – Here’s What Happened

GENinCode Plc (LON:GENI) shares were down 9.6% on Wednesday . The company traded as low as GBX 2.35 and last traded at GBX 2.35. Approximately 193,573 shares traded hands during mid-day trading, a decline of 77% from the average daily volume of 838,768 shares. The stock had previously closed at GBX 2.60.

GENinCode Trading Down 3.9%

The company has a debt-to-equity ratio of 9.28, a quick ratio of 15.89 and a current ratio of 2.60. The firm has a market capitalization of £7.17 million, a price-to-earnings ratio of -1.06 and a beta of 0.66. The business has a fifty day moving average price of GBX 2.63 and a 200 day moving average price of GBX 2.46.

GENinCode (LON:GENI) last issued its earnings results on Tuesday, September 30th. The company reported GBX (1.19) earnings per share for the quarter. GENinCode had a negative net margin of 228.70% and a negative return on equity of 289.74%. As a group, equities analysts forecast that GENinCode Plc will post -7.1299999 earnings per share for the current year.

About GENinCode

GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.

GENinCode operates business units in the UK, in the United States through GENinCode U.S. Inc and in Europe through GENinCode S.L.U.

GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset.